Clinical Trials Logo
  1. Home
  2. Adult Solid Tumor
  3. NCT04084951

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Adult Solid Tumor Clinical Trial

Official title:
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Clinical Trial Summary

This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune checkpoint inhibitors in HLA-A*02+ patients with recurrent, locally advanced or metastatic human papillomavirus strain 16 positive (HPV16+) solid tumors. The study includes patients with anal, rectal, cervical, head and neck, penile, vulvar, or vaginal cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04084951
Study type Interventional
Source SQZ Biotechnologies
Contact
Status Completed
Phase Phase 1
Start date January 28, 2020
Completion date February 9, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Active, not recruiting NCT04538625 - Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy Phase 3
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Recruiting NCT06403436 - A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT03061305 - Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Active, not recruiting NCT02568267 - Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Phase 2
Terminated NCT05357898 - Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06277804 - A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor Phase 1
Completed NCT03818347 - Hydrogen Gas for Cancer Rehabilitation N/A
Completed NCT05400265 - Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor Phase 1
Recruiting NCT04705818 - Combining Epigenetic And Immune Therapy to Beat Cancer. Phase 2
Completed NCT01269918 - A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain N/A
Suspended NCT03253575 - CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Completed NCT03760952 - Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Active, not recruiting NCT03445858 - Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Early Phase 1
Completed NCT03303365 - Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence N/A
Not yet recruiting NCT05666635 - Study of LTC004 in Subjects With Advanced Malignant Tumors Phase 1
Recruiting NCT05752552 - Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours Phase 1
Active, not recruiting NCT05147272 - Study of RP-6306 With Gemcitabine in Advanced Solid Tumors Phase 1
Terminated NCT04892043 - Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors Phase 1